Medical Oncologist
Medicines
How does ribociclib work, and who is it for?
Ribociclib is a targeted tablet for hormone receptor positive, HER2-negative breast cancer. It blocks proteins called CDK4 and CDK6 that tell cancer cells to divide, and it is always given with hormone therapy. This page explains, in general terms, how it works, why the combination matters, and who it is used for in early and advanced breast cancer.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- How does ribociclib work, and who is it for?
- The situations where ribociclib is used
- Is ribociclib likely to be considered?
- The vocabulary, in plain language
- What ribociclib can and cannot do
- Why ribociclib is paired with hormone therapy
- How ribociclib compares with other CDK4/6 inhibitors
- Myths about how ribociclib works
- Common questions about how ribociclib works
The short answer
How does ribociclib work, and who is it for?
Ribociclib, sold as Kisqali, is a targeted tablet for breast cancer that is hormone receptor positive and HER2-negative. In this kind of breast cancer, oestrogen acts like a fuel that pushes cancer cells to divide. Inside each cell, oestrogen switches on proteins called CDK4 and CDK6. These proteins work like a gatekeeper, letting the cell move past a checkpoint and begin copying itself. Ribociclib blocks CDK4 and CDK6, so the gate stays closed and cancer cells are held back from dividing. Hormone therapy lowers or blocks oestrogen, cutting the fuel supply, while ribociclib closes the gate further along the same pathway. Together they work better than hormone therapy alone, which is why ribociclib is always given with a hormone treatment such as letrozole, anastrozole or fulvestrant. It is not used for HER2-positive or triple negative breast cancer, because those cancers grow in different ways. Ribociclib is used in two main situations. In advanced breast cancer, large trials showed that adding it to hormone therapy delayed cancer growth and helped people live longer on average. In early breast cancer with a higher chance of coming back, a trial showed that adding it for three years lowered the risk of the cancer returning. Women who have not been through menopause, and men, also receive treatment to lower their own hormone levels.
It blocks a growth switch
Ribociclib stops CDK4 and CDK6 from signalling cancer cells to divide.
It works with hormone therapy
It is always combined with a hormone treatment, never used on its own.
It suits one type of breast cancer
Only hormone receptor positive, HER2-negative breast cancer is treated with it.
This page gives general information only. Whether ribociclib suits you is a decision for your oncologist.Who it is for
The situations where ribociclib is used
Your cancer type, stage and menopause status all shape whether it fits.
Advanced breast cancer, first treatment
Often combined with an aromatase inhibitor as the first treatment for cancer that has spread or come back.
Advanced breast cancer, with fulvestrant
Can be combined with fulvestrant, either as a first treatment or after earlier hormone therapy has stopped working.
Early breast cancer with higher risk
Added to an aromatase inhibitor after surgery for people whose cancer has a higher chance of coming back, based on size, grade and lymph nodes.
Your team uses your pathology report to decide.Premenopausal women and men
Ribociclib can be used, but hormone levels must first be lowered.
This usually means
- Injections such as goserelin to switch off the ovaries
- A similar hormone-lowering injection for men
- Combined with an aromatase inhibitor or fulvestrant
Quick check
Is ribociclib likely to be considered?
Situation
What generally applies
Hormone receptor positive, HER2-negative
This is the type ribociclib is designed for
HER2-positive breast cancer
Not a standard use; HER2-targeted treatment is used instead
Triple negative breast cancer
Not used, as these cancers do not rely on hormones
Existing heart rhythm problems
Needs careful review, and another option may be chosen
Pregnancy or trying to conceive
Not given in pregnancy; contraception is needed during treatment
Words you will hear
The vocabulary, in plain language
- CDK4 and CDK6
- Proteins inside cells that act as switches, letting cells divide.
- Cell cycle
- The series of steps a cell goes through to copy itself and divide.
- Hormone receptor positive
- Cancer cells that have receptors for oestrogen or progesterone and use them to grow.
- HER2-negative
- Cancer that does not have high levels of the HER2 protein.
- Targeted therapy
- Treatment aimed at specific proteins that help cancer cells grow.
- Endocrine resistance
- When cancer keeps growing despite hormone therapy.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
What ribociclib can and cannot do
Ribociclib is an important advance, but it is fair to be clear about its limits.
It slows cancer rather than removing it
In advanced breast cancer, the aim is to control the cancer for as long as possible. Most cancers eventually find a way around treatment.
Benefit varies
Trial results describe averages. Some people do very well for years, while others need a change of treatment sooner.
It needs monitoring
Regular blood tests and ECGs are part of treatment, because some side effects cause no symptoms at first.
What this page cannot tell you
It cannot tell you whether ribociclib is right for you or how much it might help. Your oncologist can explain that using your own results.
Why the combination
Why ribociclib is paired with hormone therapy
Hormone therapy alone works well for many people with hormone receptor positive breast cancer. So why add a second medicine?
Two blocks on one pathway
Hormone therapy reduces the oestrogen signal. Ribociclib blocks a step further down. Cancer cells find it harder to escape when both steps are blocked.
Delaying resistance
Over time, cancers can learn to grow despite hormone therapy. Adding ribociclib helps hold that process back for longer.
Choosing the partner medicine
Ribociclib is usually paired with an aromatase inhibitor or fulvestrant. It is not usually given with tamoxifen, because both can affect the heart rhythm.
Similar medicines
How ribociclib compares with other CDK4/6 inhibitors
Ribociclib is one of three CDK4/6 inhibitors used in breast cancer. The others are palbociclib and abemaciclib.
They share a way of working
All three block CDK4 and CDK6, and all are given with hormone therapy.
They differ in side effects and schedule
Ribociclib needs ECG checks for heart rhythm and liver tests. Abemaciclib is taken without a week off and more often causes diarrhoea. Palbociclib mainly lowers blood counts.
Your team chooses
The choice depends on your stage, other health conditions, other medicines and what is available. There is no single right answer for everyone.
Commonly believed
Myths about how ribociclib works
Ribociclib is a type of chemotherapy.
It is a targeted tablet that blocks specific proteins, and its side effects are different from chemotherapy.
It works for any type of breast cancer.
It is used only for hormone receptor positive, HER2-negative breast cancer.
Once I take ribociclib, I no longer need hormone therapy.
Ribociclib works alongside hormone therapy, and both are needed.
It is only for older women.
It can be used at any age, including before menopause, with ovarian suppression.
Questions we are asked
Common questions about how ribociclib works
Does ribociclib kill cancer cells?
Its main action is to stop cancer cells dividing, holding them in a resting state. Some cells may then die over time, and tumours can shrink, but the main aim is to keep the cancer from growing. That is why it is taken continuously in cycles rather than as a short course.
How quickly does ribociclib start working?
It starts acting on cells within days, but the effect on the cancer is judged over months. In advanced disease, your team usually does a first scan a few months after starting. Some people notice symptoms such as bone pain easing earlier, but that varies.
Why does it lower white blood cells?
Bone marrow cells that make white cells also use CDK4 and CDK6 to divide. When ribociclib blocks them, production slows for a while. This is why blood counts drop and recover in a pattern linked to the week off, and why regular blood tests are needed.
Is ribociclib used for early breast cancer in India?
Ribociclib is approved in several countries for selected early breast cancers with a higher risk of returning, and oncologists in India may consider it for suitable patients. Whether it is recommended depends on your stage, pathology and overall health, so ask your oncologist.
Does ribociclib work if the cancer is only progesterone receptor positive?
Cancers that are progesterone receptor positive but oestrogen receptor negative are uncommon, and there is less evidence for them. Your oncologist will look at the full receptor results and discuss whether a CDK4/6 inhibitor is likely to help in your situation.
Can ribociclib be used after palbociclib has stopped working?
This is an area of ongoing research. Some studies have looked at switching CDK4/6 inhibitors or continuing one with a different hormone therapy, but it is not yet standard for everyone. Your oncologist will weigh the evidence and other options with you.
Do men with breast cancer take ribociclib?
Yes, men with hormone receptor positive, HER2-negative advanced breast cancer can be treated with ribociclib. Because men make oestrogen in a different way, they usually also receive an injection to lower hormone levels when an aromatase inhibitor is used.
Will a genetic test show whether ribociclib will work?
There is currently no test that reliably predicts who will benefit most from ribociclib. The decision is based mainly on hormone receptor and HER2 results, stage and overall health. Other tests, such as genomic risk scores, may help decide treatment in early breast cancer.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- National Cancer Institute — Ribociclib
- Cancer Research UK — Ribociclib (Kisqali)
- American Cancer Society — Targeted Drug Therapy for Breast Cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.